Oral delivery of dextran-modified albumin nanoparticles loaded with shikonin for targeted therapy of colorectal cancer.

ABSTRACT:

Background

Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide.

Methods

In this study, we developed a novel nanomedicine-based therapeutic approach targeting key molecules involved in the progression of CRC. By utilizing bioinformatics tools and computer simulations, we identified SLC2A1 and PKM2 as potential therapeutic targets for CRC. Through molecular docking, we confirmed that shikonin (SHK), a bioactive compound derived from traditional herbal medicine, could effectively bind to SLC2A1 and PKM2, indicating its potential therapeutic effect. The novel SHK-loaded nanoplatform, functionalized with albumin (BSA) and glycoside modification (gBSA/SHK), was designed to enhance stability and targeted delivery to tumor si

SUBMITTER: Ren Z 

PROVIDER: S-EPMC12638471 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature